Under $2.00 stocks Message Board

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Non-Tech : Under $2.00 stocks

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next

From: Tadsamillionaire	2/9/2005 9:38:51 PM
	of 112

Peregrine's cancer drug gets OK for clinical trials The Food and Drug Administration gave clearance to go ahead with clinical trials for Peregrine Pharmaceuticals' anti-cancer drug, Tarvacin, the company said Thursday. Up to 28 patients with advanced solid tumors that no longer respond to standard cancer treatments will be enrolled at three clinical sites for the trials. The drug will be administered intravenously. Tarvacin initially was discovered by researchers at the University of Texas Southwestern in Dallas, who worked closely with Peregrine. The drug uses a therapy that binds directly to tumor blood vessels in an attempt to inhibit their growth. Tustin-based Peregrine Pharmaceuticals Inc. (NASDAQ: PPHM) is a biotech company that develops therapeutic agents that effect blood vessels and blood flow in cancer and other diseases. bizjournals.com

Report TOU Violation

Share This Post

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next